Clinical Trial Update: A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India [Phase 4]

View source ↗

Summary

A Phase 4 safety study evaluating the 13-valent pneumococcal conjugate vaccine (Prevnar 13) in healthy adults aged 18-49 in India; results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 4 | Status: COMPLETED | Results posted: 2024-04-26